Led a team of 40 finance professionals, covering treasury operations (debt and equity capital markets, currency and interest rate derivatives, cash management, and investments), pension benefits investments, insurance, investor relations, and Corporate Finance and Investment Banking; also assisted with negotiations for acquisitions above $1 billion and co-led the company’s activism and takeover defense efforts. Company officer.• Collaborated with small group of leaders to execute the IPO and split off of Elanco Animal Health; among other contributions, prepped management for debt and equity road shows, participated in ratings agency meetings, and directed allocation of IPO shares.• Issued $19.5 billion in debt across six USD offerings as well as $4.5 billion in Euro, Yen and Pound Sterling debt as part of two liability management exercises to repurchase USD debt.• Drove company’s capital markets social justice efforts yielding $365 million in debt investments, $140 million in venture capital commitments, and $10 million in deposits with minority-owned firms.• For four years, led key human resources processes for talent development, management staffing, and diversity for 1,800-person global Finance and Procurement function; colleagues noted significant improvement in collaboration, transparency, and development of female and MGM talent.

Built deep relationships with the investment community and counseled CEO and CFO on investor outreach and messaging both during times of repeated pipeline failures and falling stock prices and times of pipeline success and rising stock prices.• Spearheaded and successfully implemented decision to stop providing quarterly financial guidance.• Achieved Institutional Investor #1 ranking for Major Pharmaceuticals investor relations officer (IRO) with buy-side investors, sell-side analysts, and overall for each of the last three years in role.

Responsible for 180 finance professionals worldwide. Member of Manufacturing Policy Committee leading organization comprising over 12,000 employees, more than $3 billion in annual expenditures, over $1.5 billion in inventory, and $1 billion in capital expenditures.• Led efforts to develop – and begin an accelerated implementation of – a plan to significantly rationalize manufacturing infrastructure.• Partnered with line management to come in below expense, variance, inventory, and capital expenditure targets in 2005 and 2006.

Responsible for 40 finance professionals. Member of five-person Executive Committee leading organization comprised of 1,300 employees, including sales/marketing, manufacturing, clinical data management, and basic chemistry research and with $400 million in local market sales. All affiliate interactions conducted in Spanish.• Demonstrated proactive management of operating expenses and other income to exceed income targets every year, despite sales shortfalls.• Taken forward by European management as a top sales and marketing talent; following CEO review, was slotted for placement into a mid-sized affiliate General Manager role.

Responsible for 30 finance professionals covering treasury, tax, payroll, cost accounting, general accounting, accounts payable, and billing. Member of Executive Committee leading organization comprised of over 1,000 employees, more than $4 billion in sales (intercompany), and $1.5 billion in net income.• Led renegotiation of government tax grant, saving over $250 million in taxes; obtained the first ever 0% tax grant.

Constructed valuation analyses for licensing transactions; provided insights to structure deal terms to reflect risk and value inflection; asked by corporate business development colleagues to participate in many negotiations.• Provided financial support – and actively participated in the negotiations – for the license of Cialis, Actos, and delivery device technology for inhaled insulin as well as the early exit from a series of generic pharmaceutical agreements with an Indian partner.

Reviewed and presented to management the financial performance of the Japan affiliate; active in negotiating annual budget targets; supported affiliate business development negotiations.• Constructed negotiation strategy and supporting analysis used by management to obtain a $14 million concession from Japanese partner.

Participated in consulting projects across a range of industries, including banking, consumer goods, defense, energy, and industrials; conducted client work in Italian; active member of the firm’s global Corporate Finance practice.• Implemented a capital allocation and risk-adjusted performance measurement system to increase the return on equity of a major Italian bank.• Defined a detailed post-merger program to minimize the time and cost of integration as well as to maximize the potential savings from the integration of two banks.• Taught valuation as part of the firm’s Economic Concepts (valuation) training course.

Reviewed 10 capital projects totaling $20 million to ensure adherence to corporate strategic and financial goals; presented recommendations to the CFO.

Part of a two-person team tasked with establishing an investment banking operation for an Italian venture capitalist; resulted in relationships with/retainers from six large multinational companies.• Involved in negotiation, due diligence, and valuation for proposed £500+ million acquisition of two British airlines by a major publicly traded company; deal abandoned the day of signing.

Lived in Florence, Italy for six months to become fluent in Italian language and to study Renaissance art, architecture and history; subsequently traveled throughout Italy and Europe for 10 months

Wrote descriptive memoranda for strategic alliances between biotechnology and pharmaceutical companies and prepared industry analyses to identify acquisition candidates.• Served as lead banker to structure and negotiate a $40 million acquisition of a chemical company.

Performed financial analyses and valuations for a broad range of transactions, including leveraged buyouts, acquisitions, initial public offerings, debt refinancings, and share repurchase programs.• Partnered with client senior management and lawyers to develop roadshow materials and SEC offering documents for an initial public offering (IPO) of equity and debt.